Article(id=1322906850496225416, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322906824709648449, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1609776000000, acceptedDateStr=2021-01-05, onlineDate=1793335171578, onlineDateStr=2026-10-30, pubDate=1635523200000, pubDateStr=2021-10-30, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793335171578, onlineIssueDateStr=2026-10-30, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793335171578, creator=13701087609, updateTime=1793335171578, updator=13701087609, issue=Issue{id=1322906824709648449, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='20', pageStart='1825', pageEnd='1920', issueExtLink='null', onlineDate='null', pubDate='1635523200000', pubDateStr='2021-10-30', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793335165428, creator='13701087609', updateTime=1793337419278, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322916278284976934, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322906824709648449, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322916278284976935, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322906824709648449, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1836, endPage=1840, ext={EN=ArticleExt(id=1322906850819186825, articleId=1322906850496225416, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=A new drug for treatment of mantle cell lymphoma: Bruton's tyrosine kinase inhibitor-zanubrutinib, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Zanubrutinib is the second-generation Bruton's tyrosine kinase (BTK) inhibitor, which was approved by the U. S. FDA on November 15, 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Zanubrutinib is more selective than ibutinib and is well tolerated with common adverse reactions including neutropenia, thrombocytopenia, bruising or petechiae, upper respiratory tract infections and rashes. The action mechanism, pharmacokinetics, clinical trials and safety of zanubrutinib were reviewed in this article.

, authors=Chun-hui WANG¹, Xue-jiao ZHANG², Qian-zhou Lܹ, authorsList=Chun-hui WANG, Xue-jiao ZHANG, Qian-zhou LÜ, authorCompany=null, correspAuthors=Xue-jiao ZHANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322906851116982410, articleId=1322906850496225416, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=治疗套细胞淋巴瘤新药布鲁顿酪氨酸激酶抑制剂泽布替尼, columnId=1236331162679955859, journalTitle=中国新药杂志, columnName=新药述评与论坛, runingTitle=null, highlight=null, articleAbstract=

泽布替尼是第二代布鲁顿酪氨酸激酶（Bruton's tyrosine kinase，BTK）抑制剂，于2019年11月15日经美国FDA批准上市，用于治疗既往接受过至少1项疗法的成年套细胞淋巴瘤（mantle cell lymphoma，MCL）患者。泽布替尼的选择性优于伊布替尼，患者耐受性良好，常见不良反应包括中性粒细胞减少、血小板减少、挫伤或瘀斑、上呼吸道感染和皮疹等。本文主要介绍泽布替尼的作用机制、药动学、临床试验和安全性。

, authors=王春晖¹, 张雪皎², 吕迁洲¹, authorsList=王春晖, 张雪皎, 吕迁洲, authorCompany=null, correspAuthors=张雪皎, authorNote=, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=6r9zr3k5xq7Im5Vx41GZvg==, magXml=OLJHaZWncfPqNJGT7cwmOQ==, pdfUrl=null, pdf=LLIdxX5aH7OMG3wVcxNUIA==, pdfFileSize=779894, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=UTCkO7/qRtvxZkwikl6mwg==, mapNumber=null, fund=null)}, authors=[Author(id=1322906851578355858, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=wang.chunhui@zs-hospital.sh.cn, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906851674824852, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, authorId=1322906851578355858, language=EN, stringName=Chun-hui WANG, firstName=Chun-hui, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Zhongshan Hospital Affiliated to Fudan University, Department of Pharmacy, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906851771293845, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, authorId=1322906851578355858, language=CN, stringName=王春晖, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹复旦大学附属中山医院　药剂科，上海　200032, bio={"content":"

王春晖，男，学士，主管药师，研究方向：临床药学。E-mail：wang.chunhui@zs-hospital.sh.cn。

"}, bioImg=null, bioContent=

王春晖，男，学士，主管药师，研究方向：临床药学。E-mail：wang.chunhui@zs-hospital.sh.cn。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906851377029259, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, xref=1, ext=[AuthorCompanyExt(id=1322906851385417868, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851377029259, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Zhongshan Hospital Affiliated to Fudan University, Department of Pharmacy, Shanghai 200032, China), AuthorCompanyExt(id=1322906851393806477, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851377029259, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹复旦大学附属中山医院　药剂科，上海　200032)])]), Author(id=1322906851867762839, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zhang.xuejiao@zs-hospital.sh.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906851943260313, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, authorId=1322906851867762839, language=EN, stringName=Xue-jiao ZHANG, firstName=Xue-jiao, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²Zhongshan Hospital Affiliated to Fudan University, Department of Hematology, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906852018757786, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, authorId=1322906851867762839, language=CN, stringName=张雪皎, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²复旦大学附属中山医院　血液科，上海　200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906851486081166, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, xref=2, ext=[AuthorCompanyExt(id=1322906851498664079, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851486081166, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Zhongshan Hospital Affiliated to Fudan University, Department of Hematology, Shanghai 200032, China), AuthorCompanyExt(id=1322906851507052688, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851486081166, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²复旦大学附属中山医院　血液科，上海　200032)])]), Author(id=1322906852085866652, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906852186529950, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, authorId=1322906852085866652, language=EN, stringName=Qian-zhou LÜ, firstName=Qian-zhou, middleName=null, lastName=LÜ, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Zhongshan Hospital Affiliated to Fudan University, Department of Pharmacy, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906852253638815, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, authorId=1322906852085866652, language=CN, stringName=吕迁洲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹复旦大学附属中山医院　药剂科，上海　200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906851377029259, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, xref=1, ext=[AuthorCompanyExt(id=1322906851385417868, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851377029259, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Zhongshan Hospital Affiliated to Fudan University, Department of Pharmacy, Shanghai 200032, China), AuthorCompanyExt(id=1322906851393806477, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851377029259, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹复旦大学附属中山医院　药剂科，上海　200032)])])], keywords=[Keyword(id=1322906852358496416, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=EN, orderNo=1, keyword=zanubrutinib), Keyword(id=1322906852421410977, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=EN, orderNo=2, keyword=Bruton's tyrosine kinase inhibitor), Keyword(id=1322906852488519842, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=EN, orderNo=3, keyword=mantle cell lymphoma), Keyword(id=1322906852551434403, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=EN, orderNo=4, keyword=chronic B-cell lymphocytic leukemia), Keyword(id=1322906852618543268, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=CN, orderNo=1, keyword=泽布替尼), Keyword(id=1322906852727595173, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=CN, orderNo=2, keyword=布鲁顿酪氨酸激酶抑制剂), Keyword(id=1322906852811481254, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=CN, orderNo=3, keyword=套细胞淋巴瘤), Keyword(id=1322906852886978727, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, language=CN, orderNo=4, keyword=慢性B细胞淋巴细胞白血病)], refs=[Reference(id=1322906854321430698, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU Y, WANG H, FANG W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004[J]. Cancer, 2008, 113(4): 791-798., articleTitle=null, refAbstract=null), Reference(id=1322906854388539563, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=EPPERLA N, HAMADANI M, FENSKE TS, et al. Incidence and survival trends in mantle cell lymphoma[J]. Br J Haematol, 2018, 181(5): 703-706., articleTitle=null, refAbstract=null), Reference(id=1322906854459842732, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=OWEN C, BERINSTEIN N L, CHRISTOFIDES A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma[J]. Curr Oncol, 2019, 26(3): e233-e240., articleTitle=null, refAbstract=null), Reference(id=1322906854531145901, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=BOND DA, ALINARI L, MADDOCKS K. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions[J]. Clin Adv Hematol Oncol, 2019, 17(4): 223-233., articleTitle=null, refAbstract=null), Reference(id=1322906854610837678, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=GEISLER CH, KOLSTAD A, LAURELL A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur[J]. Br J Haematol, 2012, 158(3): 355-362., articleTitle=null, refAbstract=null), Reference(id=1322906854749249711, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=BOND DA, WOYACH JA. Targeting BTK in CLL: Beyond ibrutinib[J]. Curr Hematol Malign Rep, 2019, 14: 197-205., articleTitle=null, refAbstract=null), Reference(id=1322906854820552880, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=TAM C, GRIGG AP, OPAT S, et al. The BTK inhibitor, BGB-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial[J]. Blood, 2015, 126(23): 832., articleTitle=null, refAbstract=null), Reference(id=1322906854904438961, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=LI N, SUN Z, LIU Y, et al. BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor[J]. Cancer Res, 2015, 75(Suppl 15): S2597., articleTitle=null, refAbstract=null), Reference(id=1322906854971547826, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. BRUKINSA (zanubrutinib)[EB/OL]. (2019-11-14) [2020-01-24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1322906855097376947, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=HENDRIKS RW, YUVARAJ S, KIL LP. Targeting Bruton's tyrosine kinase in B cell malignancies[J]. Nat Rev Cancer, 2014, 14(4): 219-232., articleTitle=null, refAbstract=null), Reference(id=1322906855189651636, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=GUO YH, LIU Y, HU N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase[J]. J Med Chem, 2019, 62: 7923-7940., articleTitle=null, refAbstract=null), Reference(id=1322906855273537717, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=MU S, TANG ZY, NOVOTNY W, et al. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects[J/OL]. Cancer Chemother Pharmacol, 2020, 85(2): 391-399. DOI: 10.1007/s00280-019-04015-w., articleTitle=null, refAbstract=null), Reference(id=1322906855340646582, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH. A phase Ⅰ/Ⅱ, open-label, multiple-dose, dose escalation and expansion study to investigate the safety and pharmacokinetics of the BTK inhibitor BGB-3111 in subjects with B-cell lymphoid malignancies[EB/OL]. (2019-11-01) [2020-01-24]. https://clinicaltrials.gov/ct2/show/NCT02343120., articleTitle=null, refAbstract=null), Reference(id=1322906855420338359, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH. A single-arm, open-label, multicenter phase 2 study to evaluate efficacy and safety of BGB-3111, a Bruton's tyrosine kinase (BTK) inhibitor, in subjects with refractory or relapsed mantle cell lymphoma (MCL)[EB/OL]. (2020-01-18) [2020-01-24]. https://clinicaltrials.gov/ct2/show/NCT03206970., articleTitle=null, refAbstract=null), Reference(id=1322906855491641528, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=TAM CS, TROTMAN J, OPAT S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL[J]. Blood, 2019, 134(11): 851-859., articleTitle=null, refAbstract=null), Reference(id=1322906855558750393, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=TAM CS, WANG M, SIMPSON D, et al. Updated safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma[J]. Blood, 2018, 132(Suppl 1): S1592., articleTitle=null, refAbstract=null), Reference(id=1322906855638442170, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=SONG Y, ZHOU K, ZOU D, et al. Safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial[J]. Blood, 2018, 132(Suppl 1): S148., articleTitle=null, refAbstract=null), Reference(id=1322906855705551035, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG ML, RULE S, MARTIN P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2013, 369(6): 507-516., articleTitle=null, refAbstract=null), Reference(id=1322906855772659900, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=WU JJ, LIU C, TSUI ST, et al. Second-generation inhibitors of Bruton tyrosine kinase[J]. J Hematol Oncol, 2016, 9: 80., articleTitle=null, refAbstract=null), Reference(id=1322906855843963069, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=CULL G, SIMPSON D, OPAT S, et al. Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial[J]. Blood, 2019, 134(Suppl 1): S500., articleTitle=null, refAbstract=null), Reference(id=1322906855919460542, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=TAM CS, ROBAK T, GHIA P, et al. Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del (17p): initial results from Arm C of the Sequoia (BGB-3111-304) Tria[J]. Blood, 2019, 134(Suppl 1): S499., articleTitle=null, refAbstract=null), Reference(id=1322906856011735231, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=BeiGene. BeiGene announces phase 1b clinical results of Zanubrutinib in combination with GAZYVA^® (obinutuzumab) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or follicular lymphoma at the 15th international conference on malignant lymphoma (ICML)[EB/OL]. (2019-06-20) [2020-01-24]. https://www.globenewswire.com/news-release/2019/06/20/1872013/0/en/BeiGene-Announces-Phase-1b-Clinical-Results-of-Zanubrutinib-in-Combination-with-GAZYVA-Obinutuzumab-in-Patients-with-Chronic-Lymphocytic-Leukemia-Small-Lymphocytic-Lymphoma-or-Foll.html., articleTitle=null, refAbstract=null), Reference(id=1322906856087232704, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=FOWLER NH, TROTMAN J, AUER R, et al. Randomized phase 2 zanubrutinib (BGB-3111)+obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma (R/R FL)[J]. Blood, 2019, 134(Suppl 1): S5252., articleTitle=null, refAbstract=null), Reference(id=1322906856196284609, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH. Phase 2 study of zanubrutinib, obinutuzumab, and venetoclax in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)[EB/OL]. (2019-07-15) [2020-01-24]. https://clinicaltrials.gov/ct2/show/NCT03824483., articleTitle=null, refAbstract=null), Reference(id=1322906856255004866, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=OPAT S, MARCUS R, PORTELL CA, et al. Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma[J]. Blood, 2019, 134(Suppl 1): S5256., articleTitle=null, refAbstract=null), Reference(id=1322906856326308035, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=THOMPSON PA, BURGER JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)[J]. Expert Opin Invest Drugs, 2018, 27(1): 31-42., articleTitle=null, refAbstract=null)], funds=[Fund(id=1322906853033779368, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, awardId=2016ZB0301, language=CN, fundingSource=上海市卫生计生系统重要薄弱学科建设项目(2016ZB0301), fundOrder=null, country=null), Fund(id=1322906854212378793, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, awardId=shslczdzk06504, language=CN, fundingSource=上海市临床重点专科项目(shslczdzk06504), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1322906851377029259, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, xref=1, ext=[AuthorCompanyExt(id=1322906851385417868, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851377029259, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Zhongshan Hospital Affiliated to Fudan University, Department of Pharmacy, Shanghai 200032, China), AuthorCompanyExt(id=1322906851393806477, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851377029259, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹复旦大学附属中山医院　药剂科，上海　200032)]), AuthorCompany(id=1322906851486081166, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, xref=2, ext=[AuthorCompanyExt(id=1322906851498664079, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851486081166, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Zhongshan Hospital Affiliated to Fudan University, Department of Hematology, Shanghai 200032, China), AuthorCompanyExt(id=1322906851507052688, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906850496225416, companyId=1322906851486081166, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²复旦大学附属中山医院　血液科，上海　200032)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I20/1836, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I20/1836, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I20/1836, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I20/1836, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1635523200000, fullTextJson=null, articleText=null, reference=null)